Evidence map›Paper›PMID 32443727›Full record

ReviewCells2020

IGFBP-3/IGFBP-3 Receptor System as an Anti-Tumor and Anti-Metastatic Signaling in Cancer.

Qing Cai, Mikhail Dozmorov, Youngman Oh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. IGFBP-3 enhances irinotecan efficacy in colorectal cancerResearch in pharmaceutical sciences · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. The role of adipogenic niche resident cells in colorectal cancer progression in relation to obesity.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  18. Article
  19. Review
  20. Review

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Qing CaiDepartment of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA.
Mikhail DozmorovDepartment of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-0086-8358
Youngman OhDepartment of Pathology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA.ORCID 0000-0002-7324-2073
Virginia Commonwealth University Medical Center · USVirginia Commonwealth University · US

Funding

Therapeutic potential of neutrophil protease inhibitors in colon cancerR21CA216685 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI OH, YOUNGMAN · 2018 to 2019
$365k
NCI NIH HHS R21 CA216685
6 · The paper itself

Abstract

Insulin-like growth factor binding protein-3 (IGFBP-3) is a p53 tumor suppressor-regulated protein and a major carrier for IGFs in circulation. Among six high-affinity IGFBPs, which are IGFBP-1 through 6, IGFBP-3 is the most extensively investigated IGFBP species with respect to its IGF/IGF-I receptor (IGF-IR)-independent biological actions beyond its endocrine/paracrine/autocrine role in modulating IGF action in cancer. Disruption of IGFBP-3 at transcriptional and post-translational levels has been implicated in the pathophysiology of many different types of cancer including breast, prostate, and lung cancer. Over the past two decades, a wealth of evidence has revealed both tumor suppressing and tumor promoting effects of IGF/IGF-IR-independent actions of IGFBP-3 depending upon cell types, post-translational modifications, and assay methods. However, IGFBP-3's anti-tumor function has been well accepted due to identification of functional IGFBP-3-interacting proteins, putative receptors, or crosstalk with other signaling cascades. This review mainly focuses on transmembrane protein 219 (TMEM219), which represents a novel IGFBP-3 receptor mediating antitumor effect of IGFBP-3. Furthermore, this review delineates the potential underlying mechanisms involved and the subsequent biological significance, emphasizing the clinical significance of the IGFBP-3/TMEM219 axis in assessing both the diagnosis and the prognosis of cancer as well as the therapeutic potential of TMEM219 agonists for cancer treatment.

Indexed as

Signal TransductionAmino Acid SequenceAnimalsHumansInsulin-Like Growth Factor Binding Protein 3Neoplasm MetastasisNeoplasmsReceptors, Cell SurfaceSurvival AnalysisInsulin-Like Growth Factor Binding Protein 3Receptors, Cell Surfaceagonistsanti-metastaticanti-tumorIGFBP-3IGFBP-3RIGF systemmAb therapyTMEM219

Identifiers

PMID32443727
PMCPMC7290346
OpenAlexW3027760124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.